Squarepoint Ops LLC Buys 54,791 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Squarepoint Ops LLC boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 22.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 295,824 shares of the company’s stock after acquiring an additional 54,791 shares during the quarter. Squarepoint Ops LLC’s holdings in Tarsus Pharmaceuticals were worth $18,619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Nykredit A S purchased a new position in Tarsus Pharmaceuticals in the 2nd quarter worth approximately $106,000. California State Teachers Retirement System grew its holdings in shares of Tarsus Pharmaceuticals by 5,971.9% in the second quarter. California State Teachers Retirement System now owns 2,288,813 shares of the company’s stock worth $144,058,000 after purchasing an additional 2,251,118 shares during the last quarter. Pale Fire Capital SE increased its stake in shares of Tarsus Pharmaceuticals by 73.4% in the second quarter. Pale Fire Capital SE now owns 9,802 shares of the company’s stock worth $617,000 after buying an additional 4,150 shares during the period. Hsbc Holdings PLC increased its stake in shares of Tarsus Pharmaceuticals by 295.0% in the second quarter. Hsbc Holdings PLC now owns 38,090 shares of the company’s stock worth $2,429,000 after buying an additional 28,447 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Tarsus Pharmaceuticals by 149.9% during the 2nd quarter. Wellington Management Group LLP now owns 40,202 shares of the company’s stock valued at $2,530,000 after buying an additional 24,117 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 10,000 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $61.55, for a total transaction of $615,500.00. Following the transaction, the chief executive officer directly owned 847,991 shares of the company’s stock, valued at $52,193,846.05. This represents a 1.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the completion of the transaction, the director directly owned 106,786 shares in the company, valued at $6,633,546.32. The trade was a 10.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 75,381 shares of company stock worth $5,477,298. 9.64% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Stock Down 5.1%

Shares of NASDAQ:TARS opened at $82.77 on Thursday. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. The stock has a fifty day simple moving average of $67.53 and a two-hundred day simple moving average of $66.45. Tarsus Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $91.53. The stock has a market capitalization of $3.63 billion, a price-to-earnings ratio of -75.94 and a beta of 0.54.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The firm had revenue of $173.91 million for the quarter, compared to the consensus estimate of $169.65 million. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Guggenheim dropped their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. Jefferies Financial Group upped their price target on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday. Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Finally, Mizuho cut their price target on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $92.57.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.